4E20 | date | ![]() |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | |||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | |||||||||||||
ligand | 0MY | enzyme |
| ||||||||||||
Gene Ontology ![]() |
| ||||||||||||||
Primary reference | Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor., Argiriadi MA, Goedken ER, Banach D, Borhani DW, Burchat A, Dixon RW, Marcotte D, Overmeyer G, Pivorunas V, Sadhukhan R, Sousa S, Moore NS, Tomlinson M, Voss J, Wang L, Wishart N, Woller K, Talanian RV, BMC Struct Biol. 2012 Sep 20;12(1):22. PMID:22995073 |
Data retrieval |
![]() |
View 4E20 in 3D |
![]() |
Structure-derived information |
Sequence-derived information |
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |